The DOI matches its Crossref record.
Structural and Functional Implications of C-Terminal Regions of α-Synuclein
Abstract
Aggregation of alpha-synuclein is thought to play a major role in the pathogenesis of Parkinson's disease (PD), which is characterized by the presence of intracytoplasmic Lewy bodies (LB) in the brain. alpha-Synuclein and its deletion mutants are largely unfolded proteins with random coil structures as revealed by CD spectra, fluorescence spectra, gel filtration chromatography, and ultracentrifugation. On the basis of its highly unfolded and flexible conformation, we have investigated the chaperone-like activity of alpha-synuclein in vitro. In our experiments, alpha-synuclein inhibited the aggregation of model substrates and protected the catalytic activity of alcohol dehydrogenase and rhodanese during heat stress. In addition, alpha-synuclein inhibited the initial aggregation of reduced/denatured lysozyme on the refolding pathway. Interestingly, deletion of the C-terminal regions led to the abolishment of chaperone activity, although largely unstructured conformations are maintained. Moreover, alpha-synuclein could inhibit the aggregation of various Escherichia coli cellular proteins during heat stress, and C-terminal deletion mutants could not provide any protection to these cellular proteins. Results with synthetic C-terminal peptides and C-terminal deletion mutants suggest that the second acidic repeat, (125)YEMPSEEGYQDYEPEA(140), is important for the chaperone activity of alpha-synuclein, and C-terminal deletion leads to the facilitated aggregation with the elimination of chaperone activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
-Synuclein in Parkinson's Disease
Stefanis, L. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009399 · Cited by 1,446
Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling
Uversky, V. N., Oldfield, C. J., & Dunker, A. K. (2005) · Journal of Molecular Recognition · doi:10.1002/jmr.747 · Cited by 847
Introducing Protein Intrinsic Disorder
Habchi, J., Tompa, P., Longhi, S., & Uversky, V. N. (2014) · Chemical Reviews · doi:10.1021/cr400514h · Cited by 756
Cell Biology and Pathophysiology of α-Synuclein
Burré, J., Sharma, M., & Südhof, T. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024091 · Cited by 579
The Synaptic Function of α-Synuclein
Burré, J. (2015) · Journal of Parkinson's Disease · doi:10.3233/jpd-150642 · Cited by 573
The role of structural disorder in the function of RNA and protein chaperones
Tompa, P., & Csermely, P. (2004) · The FASEB Journal · doi:10.1096/fj.04-1584rev · Cited by 553
Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease
Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., Seubert, P., Lee, M., Goldstein, J., Chilcote, T., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.010 · Cited by 542
α-Synuclein misfolding and aggregation: Implications in Parkinson’s disease pathogenesis
Mehra, S., Sahay, S., & Maji, S. K. (2019) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2019.03.001 · Cited by 499
Li, W., West, N., Colla, E., Pletnikova, O., Troncoso, J. C., Marsh, L., Dawson, T. M., Jäkälä, P., Hartmann, T., Price, D. L., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406976102 · Cited by 472
α-synuclein in the pathophysiology of Alzheimer’s disease
Twohig, D., & Nielsen, H. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0320-x · Cited by 374
Oueslati, A., Fournier, M., & Lashuel, H. A. (2010) · Progress in Brain Research · doi:10.1016/s0079-6123(10)83007-9 · Cited by 347
α‐Synuclein and Parkinson's disease
Recchia, A., Debetto, P., Negro, A., Guidolin, D., Skaper, S. D., & Giusti, P. (2004) · The FASEB Journal · doi:10.1096/fj.03-0338rev · Cited by 318
Functional Consequences of α-Synuclein Tyrosine Nitration
Hodara, R., Norris, E. H., Giasson, B. I., Mishizen-Eberz, A. J., Lynch, D. R., Lee, V. M.-Y., & Ischiropoulos, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408906200 · Cited by 286
Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease
Dev, K. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00140-0 · Cited by 263
NMR of α‐synuclein–polyamine complexes elucidates the mechanism and kinetics of induced aggregation
Fernández, C. O., Hoyer, W., Zweckstetter, M., Jares‐Erijman, E. A., Subramaniam, V., Griesinger, C., & Jovin, T. M. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600211 · Cited by 255
Role of α-Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease
Allen Reish, H. E., & Standaert, D. G. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-140491 · Cited by 244
Roeters, S. J., Iyer, A., Pletikapić, G., Kogan, V., Subramaniam, V., & Woutersen, S. (2017) · Scientific Reports · doi:10.1038/srep41051 · Cited by 146
Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies
Brás, I. C., & Outeiro, T. F. (2021) · Cells · doi:10.3390/cells10020375 · Cited by 136
Lou, H., Montoya, S. E., Alerte, T. N. M., Wang, J., Wu, J., Peng, X., Hong, C.-S., Friedrich, E. E., Mader, S. A., Pedersen, C. J., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.100867 · Cited by 115
Olivares, D., Huang, X., Branden, L., Greig, N. H., & Rogers, J. T. (2009) · International Journal of Molecular Sciences · doi:10.3390/ijms10031226 · Cited by 93
Metadata
- Authors
- Kim, T. D., Paik, S. R., & Yang, C.-H.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2002-10-23
- Volume
- 41
- Issue
- 46
- Pages
- 13782-13790
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2018481846
- Cited by
- 162
- References
- 0
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.